INCY Incyte Corporation - Fundamental Analysis
NEUTRAL
Sign in to save
Save to watchlist or track a position.
INCY Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$106.21
Analyst Target
$102.38
-3.6%
Downside
52W High
$112.29
52W Low
$53.56
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Confidence
72%
The Advanced Deterministic Scorecard reveals a mixed financial profile for INCY, with a weak Piotroski F-Score of 4/9 indicating marginal financial health, and no available Altman Z-Score preventing a clear distress risk assessment. Despite strong profitability metrics—evidenced by a 31.63% operating margin, 30.39% ROE, and robust 290.7% YoY earnings growth—the stock trades above its Graham defensive value of $56.11 at $106.21, supported by a forward P/E of 13.80 that suggests some growth optimism. However, bearish insider activity, inconsistent earnings beats over the past two years, and a weak technical trend score of 10/100 counterbalance the strong fundamentals. Relative to peers, INCY shows superior growth and profitability but faces valuation and sentiment headwinds.
Key Strengths
Exceptional profitability with ROE of 30.39% and operating margin of 31.63%, well above sector averages
Strong year-over-year revenue (20.00%) and earnings growth (290.70%), indicating accelerating top- and bottom-line performance
Exceptionally low debt burden with a Debt/Equity ratio of just 0.01, providing significant financial flexibility
High cash conversion efficiency implied by strong operating margin and positive free cash flow trajectory
Analyst recommendation consensus is 'buy' with a target price of $102.38, close to current market price
Key Risks
Weak Piotroski F-Score of 4/9 suggests deteriorating financial stability and limited strength across key balance sheet and earnings quality metrics
Bearish insider sentiment with $32.43M in net insider sales over the last 6 months and zero buy transactions
High volatility in quarterly earnings surprises, including multiple large negative misses (e.g., -264.5% in Q3 2024)
Current price of $106.21 is nearly double the Graham Number ($56.11), indicating significant overvaluation on a defensive basis
Technical trend score of 10/100 signals strong near-term bearish momentum despite longer-term positive returns
AI Fair Value Estimate
Based on comprehensive analysis
$98.5
-7.3% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare INCY against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning INCY from our newsroom.
Newest → oldest
No matching news yet.